Home | deutsch  | Plain Language | Legals | Data Protection | Sitemap | Intranet | KIT
Portrait Monika Landgraf
Contact:
Monika Landgraf
Head of Corporate Communications, Chief Press Officer

Phone: +49 721 608-47414
Fax: +49 721 608-43658
presseNpu0∂kit edu

Margarete Lehné
Contact:

Margarete Lehné
Deputy Head of Press Office
phone: +49 721 608-21157
margarete lehne∂kit edu

Subscription of Press Releases

RSS-Feed

Press Release 087/2019

Turbo Chip for Drug Development

KIT Scientists Develop Process that Facilitates and Accelerates Chemical Synthesis and Biological Screening by Combining All Steps on a Chip
2019_087_Ein Turbochip fuer die Medikamentenentwicklung_72dpi
Array of microdroplets with various reactants on the chemBIOS chip-based synthesis platform. (Photo: Maximilian Benz, KIT)

In spite of increasing demand, the number of newly developed drugs decreased continuously in the past decades. The search for new active substances, their production, characterization, and screening for biological effectiveness are very complex and costly. One of the reasons is that all three steps have been carried out separately so far. Scientists of Karlsruhe Institute of Technology (KIT) have now succeeded in combining these processes on a chip and, hence, facilitating and accelerating the procedures to produce promising substances. Thanks to miniaturization, also costs can be reduced significantly. The results are now published in Nature Communications (DOI 10.1038/s41467-019-10685-0).

 

Drug development is based on high-throughput screening of large compound libraries. However, the lack of miniaturized and parallelized methodologies for high-throughput chemical synthesis in the liquid phase and incompatibility of synthesis of bioactive compounds and screening for their biological effect have led to a strict separation of these steps so far. This makes the process expensive and inefficient. “For this reason, we have developed a platform that combines synthesis of compound libraries with biological high-throughput screening on a single chip,” says Maximilian Benz of KIT’s Institute of Toxicology and Genetics (ITG). This so-called chemBIOS platform is compatible with both organic solvents for synthesis and aqueous solutions for biological screenings. “We use the chemBIOS platform to perform 75 parallel three-component reactions for synthesis of a library of lipids, i.e. fats, followed by characterization using mass spectroscopy, on-chip formation of lipoplexes, and biological cell screening,” Benz adds. Lipoplexes are nucleic acid-lipid complexes that can be taken up by eukaryotic, i.e. human and animal, cells. “The entire process from library synthesis to cell screening takes only three days and about 1 ml of total solution, demonstrating the potential of the chemBIOS technology to increase efficiency and accelerate screenings and drug development,” Benz points out. Usually, such processes need several liters of reactants, solvents, and cell suspensions.

 

Recently, the chemBIOS technology was nominated for one of the first three places of KIT’s NEULAND Innovation Prize 2019 by a jury of representatives of research and industry.

 

Drug Development: Big Effort and Few Hits

Due to the immense time expenditure and spatial and methodological separation of the synthesis of compounds, screening, and clinical studies, development of new drugs often takes more than 20 years and costs between two and four billion dollars.

 

The early phase of drug development is traditionally based on three areas of science: chemists synthesize a big library of various molecules. All compounds are produced, isolated, and characterized separately. Then, biologists analyze the molecule library for biological activity. Highly active compounds, so-called hits, are returned to chemistry. Based on this pre-selection, chemists synthesize further variations of these compounds. These secondary molecule libraries then contain optimized compounds. After this cycle has been repeated several times, a few promising compound candidates are transferred to the medical part of drug development, in which these compounds are tested in clinical studies. Of several then thousands of compounds subjected to first screenings, only one or sometimes no compound reaches the last step of drug development: approval of the new drug. This process is time-consuming and requires a large range of ma-terials and solvents. This makes development more expensive and slower and also limits the number of substances screened to a fea-sible number.

 

Original Publication (Open Access):

Maximilian Benz, Mijanur R. Molla, Alexander Böser, Alisa Rosenfeld, Pavel A. Levkin: Marrying chemistry with biology by combining on-chip solution-based combinatorial synthesis and cellular screening, Nature Communications 2019, DOI: 10.1038/s41467-019-10685-0

https://www.nature.com/articles/s41467-019-10685-0

 

More about the KIT Center Materials in Technical and Life Sciences: www.materials.kit.edu/index.php

 

Being „The Research University in the Helmholtz Association“, KIT creates and imparts knowledge for the society and the environment. It is the objective to make significant contributions to the global challenges in the fields of energy, mobility and information. For this, about 9,300 employees cooperate in a broad range of disciplines in natural sciences, engineering sciences, economics, and the humanities and social sciences. KIT prepares its 25,100 students for responsible tasks in society, industry, and science by offering research-based study programs. Innovation efforts at KIT build a bridge between important scientific findings and their application for the benefit of society, economic prosperity, and the preservation of our natural basis of life.

rl, 02.07.2019

Press contact:

Regina Link
Redakteurin/Pressereferentin
Tel.: +49 721 608-21158
regina linkEqw1∂kit edu
The photo in the best quality available to us may be requested by
presseIxd5∂kit edu or phone: +49 721 608-47414.

The press release is available as a PDF file.